MX2022013998A - Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas. - Google Patents
Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.Info
- Publication number
- MX2022013998A MX2022013998A MX2022013998A MX2022013998A MX2022013998A MX 2022013998 A MX2022013998 A MX 2022013998A MX 2022013998 A MX2022013998 A MX 2022013998A MX 2022013998 A MX2022013998 A MX 2022013998A MX 2022013998 A MX2022013998 A MX 2022013998A
- Authority
- MX
- Mexico
- Prior art keywords
- baff
- april
- immunomodulatory proteins
- cell
- methods
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 8
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 6
- 230000002401 inhibitory effect Effects 0.000 title 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 2
- 230000020385 T cell costimulation Effects 0.000 abstract 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
En la presente se proporcionan proteínas inmunomoduladoras que exhiben actividad neutralizante de BAFF y APRIL (o heterotrímeros de BAFF/APRIL) solas o también acopladas con inhibición de la coestimulación de células T. Las proteínas inmunomoduladoras proporcionadas en la presente incluyen dominios variantes de antígeno de maduración de células B (BCMA) solas y proteínas inmunomoduladoras multidominio que inhiben respuestas de células B y también pueden inhibir la coestimulación de células T. También se proporcionan moléculas de ácido nucleico que codifican para las proteínas inmunomoduladoras. Las proteínas inmunomoduladoras proporcionan utilidad terapéutica para una variedad de enfermedades y condiciones inmunológicas. También proporcionan composiciones y métodos para preparar y utilizar esas proteínas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063022373P | 2020-05-08 | 2020-05-08 | |
US202063034361P | 2020-06-03 | 2020-06-03 | |
US202063080643P | 2020-09-18 | 2020-09-18 | |
PCT/US2021/031432 WO2021226553A2 (en) | 2020-05-08 | 2021-05-07 | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013998A true MX2022013998A (es) | 2023-02-16 |
Family
ID=76270049
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013999A MX2022013999A (es) | 2020-05-08 | 2021-05-07 | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas. |
MX2022013998A MX2022013998A (es) | 2020-05-08 | 2021-05-07 | Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013999A MX2022013999A (es) | 2020-05-08 | 2021-05-07 | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20210388054A1 (es) |
EP (2) | EP4146684A2 (es) |
JP (2) | JP2023525032A (es) |
KR (2) | KR20230029622A (es) |
CN (4) | CN117736297A (es) |
AU (2) | AU2021267276A1 (es) |
BR (2) | BR112022022433A2 (es) |
CA (2) | CA3178882A1 (es) |
CL (1) | CL2022003104A1 (es) |
CO (1) | CO2022017780A2 (es) |
IL (2) | IL297981A (es) |
MX (2) | MX2022013999A (es) |
PE (1) | PE20230494A1 (es) |
TW (1) | TW202208414A (es) |
WO (2) | WO2021226551A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
WO2021128027A1 (zh) * | 2019-12-24 | 2021-07-01 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白及其用途 |
AU2022269139A1 (en) * | 2021-05-07 | 2023-11-16 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023089500A1 (en) * | 2021-11-17 | 2023-05-25 | Aurinia Pharmaceuticals Inc. | B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors |
WO2023236967A1 (zh) * | 2022-06-08 | 2023-12-14 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗重症肌无力的方法 |
WO2024044721A1 (en) * | 2022-08-25 | 2024-02-29 | University Of Washington | Injectable recombinant protein-based hydrogels for therapeutic delivery |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
CA2102623C (en) | 1991-05-06 | 2003-04-22 | Jeffrey Schlom | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69534702T2 (de) | 1994-09-23 | 2006-08-24 | The University Of British Columbia, Vancouver | Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen |
EP1016418B1 (en) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP2230307A1 (en) | 1996-10-25 | 2010-09-22 | Human Genome Sciences, Inc. | Neutrokine alpha |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
EP1102790B1 (en) | 1998-08-07 | 2014-05-07 | University of Washington | Immunological Herpes Simplex Virus antigens and methods for use thereof |
TR200101998T2 (tr) | 1999-01-07 | 2002-06-21 | Zymogenetics, Inc. | Çözünür reseptör BR 43x2 ve kullanım metodları |
US7833529B1 (en) * | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
ES2478635T3 (es) | 1999-08-09 | 2014-07-22 | Targeted Genetics Corporation | Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios |
DK1255558T3 (da) | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-april antistoffer og hybridomaceller |
US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
DK1297013T3 (da) | 2000-04-27 | 2006-12-27 | Biogen Idec Inc | Anvendelse af TACI som antitumormiddel |
EP1746106A3 (en) | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Use of TACI as an anti-tumor agent |
US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Bcma及びtaciの両者を結合する抗体 |
CA2446734A1 (en) | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
SI1436003T1 (sl) | 2001-05-24 | 2010-02-26 | Zymogenetics Inc | TACI-imunoglobulinski fuzijski proteini |
WO2003014294A2 (en) | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
EP1461073B1 (en) | 2001-11-30 | 2010-01-06 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Peptide agonists of prostate-specific antigen, and uses therefor |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
CA2492447A1 (en) | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
CA2501459A1 (en) | 2002-10-11 | 2004-04-22 | Zymogenetics, Inc. | Production of homotrimeric fusion proteins |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
KR20060027801A (ko) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | B 세포 장애에 대한 조합 요법 |
MXPA06004301A (es) | 2003-10-20 | 2006-06-05 | Biogen Idec Inc | Regimenes terapeuticos para antagonistas del factor de activacion de celulas b. |
PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
EP1919950A1 (en) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimized fc variants |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
CA2585927A1 (en) | 2004-11-04 | 2006-05-18 | Genentech, Inc. | Polypeptides that bind baff and/or april |
US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
JP2008526205A (ja) * | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Br3に結合するポリペプチド及びその使用 |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
CA2618763A1 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
EP1922080A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
US20090226440A1 (en) | 2005-08-12 | 2009-09-10 | Shane Grey | Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease |
WO2007030803A2 (en) | 2005-09-09 | 2007-03-15 | Zymogenetics, Inc. | Method for preparing trimeric proteins |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
KR20140077946A (ko) | 2005-10-13 | 2014-06-24 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
CN101489573B (zh) | 2006-05-15 | 2013-05-22 | 阿雷斯贸易股份有限公司 | 用TACI-Ig融合分子治疗自身免疫疾病的方法 |
JP2010501622A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Fc−融合タンパク質の精製法 |
US8513393B2 (en) | 2006-08-28 | 2013-08-20 | Ares Trading S.A. | Process for the purification of Fc-containing proteins |
WO2008025747A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-fusion proteins |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
US20100063257A1 (en) | 2007-01-26 | 2010-03-11 | Merck Serono Sa | Purification of FC-TACI Fusion Proteins Using the Oilbody Technology |
ES2422479T3 (es) | 2007-03-27 | 2013-09-11 | Zymogenetics Inc | Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias |
JP2010530000A (ja) * | 2007-06-13 | 2010-09-02 | ザイモジェネティクス,インコーポレイティド | アタシセプトなどのTACI−Ig融合タンパク質を用いた自己免疫疾患を治療するための投薬法 |
CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
AU2008314689A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
JP5469077B2 (ja) | 2007-11-12 | 2014-04-09 | アレス トレーディング ソシエテ アノニム | Taci−免疫グロブリン融合タンパク質のための調製物 |
EP2219674A1 (en) | 2007-11-12 | 2010-08-25 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
US20100261887A1 (en) | 2007-11-12 | 2010-10-14 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
EP3342872A1 (en) | 2007-12-11 | 2018-07-04 | The University of North Carolina at Chapel Hill | Polypurine tract modified retroviral vectors |
WO2009132058A2 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
WO2009134633A1 (en) | 2008-05-01 | 2009-11-05 | Zymogenetics, Inc. | Levels of blys/april heterotrimers in serum and use in diagnostic methods |
EP2310409A2 (en) | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
WO2010136480A1 (en) | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
WO2011109280A1 (en) * | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
CN101851278B (zh) | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
US20110311548A1 (en) | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
WO2012032112A1 (en) | 2010-09-10 | 2012-03-15 | Cellerix, S.A. | Stem cell culture media and methods |
CN102085368B (zh) | 2011-01-19 | 2013-06-12 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc変異体 |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
HUE033008T2 (hu) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | FC fúziós proteinek, amelyek tartalmaznak új linkereket |
WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
WO2013130684A1 (en) | 2012-02-27 | 2013-09-06 | Amunix Operating Inc. | Xten-folate conjugate compositions and methods of making same |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP2956468B1 (en) | 2013-02-12 | 2020-06-10 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
WO2015172305A1 (zh) * | 2014-05-12 | 2015-11-19 | 上海康岱生物医药技术股份有限公司 | 抑制taci-baff复合物形成的融合蛋白及其制法和用途 |
MX2017000630A (es) | 2014-07-15 | 2017-04-27 | Immune Design Corp | Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral. |
SG10201913682QA (en) | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
CR20180318A (es) * | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3474867A4 (en) | 2016-06-24 | 2020-05-20 | iCell Gene Therapeutics LLC | CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
CN110945030A (zh) | 2017-06-20 | 2020-03-31 | 丹娜法伯癌症研究院 | 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法 |
EP3675897A1 (en) | 2017-09-01 | 2020-07-08 | Dana Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
GB201720426D0 (en) | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
KR20200128054A (ko) | 2018-03-02 | 2020-11-11 | 알로젠 테라퓨틱스 인코포레이티드 | 유도성 키메라 사이토카인 수용체 |
CN110522908A (zh) | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
WO2020028572A2 (en) | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
WO2020061376A2 (en) | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
AU2019377854A1 (en) | 2018-11-08 | 2021-05-27 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
JP2022510276A (ja) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd86バリアント免疫調節タンパク質およびその使用 |
MX2021012607A (es) | 2019-04-17 | 2022-03-11 | Alpine Immune Sciences Inc | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. |
WO2020252421A2 (en) | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
CA3154191A1 (en) | 2019-09-13 | 2021-03-18 | Kyowa Kirin Co., Ltd. | Dcr3 variant |
JP7326500B2 (ja) | 2019-12-10 | 2023-08-15 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質医薬品製剤 |
WO2021128027A1 (zh) | 2019-12-24 | 2021-07-01 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白及其用途 |
-
2021
- 2021-05-07 EP EP21730004.5A patent/EP4146684A2/en active Pending
- 2021-05-07 CA CA3178882A patent/CA3178882A1/en active Pending
- 2021-05-07 IL IL297981A patent/IL297981A/en unknown
- 2021-05-07 BR BR112022022433A patent/BR112022022433A2/pt unknown
- 2021-05-07 CN CN202311249622.3A patent/CN117736297A/zh active Pending
- 2021-05-07 CN CN202310582491.4A patent/CN116903727A/zh active Pending
- 2021-05-07 JP JP2022567472A patent/JP2023525032A/ja active Pending
- 2021-05-07 CN CN202180047593.5A patent/CN116194467A/zh active Pending
- 2021-05-07 JP JP2022567473A patent/JP2023525033A/ja active Pending
- 2021-05-07 WO PCT/US2021/031430 patent/WO2021226551A1/en unknown
- 2021-05-07 BR BR112022022524A patent/BR112022022524A2/pt unknown
- 2021-05-07 MX MX2022013999A patent/MX2022013999A/es unknown
- 2021-05-07 IL IL297980A patent/IL297980A/en unknown
- 2021-05-07 EP EP21730003.7A patent/EP4146683A1/en active Pending
- 2021-05-07 MX MX2022013998A patent/MX2022013998A/es unknown
- 2021-05-07 AU AU2021267276A patent/AU2021267276A1/en active Pending
- 2021-05-07 KR KR1020227043140A patent/KR20230029622A/ko unknown
- 2021-05-07 PE PE2022002607A patent/PE20230494A1/es unknown
- 2021-05-07 CA CA3178885A patent/CA3178885A1/en active Pending
- 2021-05-07 AU AU2021268033A patent/AU2021268033A1/en active Pending
- 2021-05-07 KR KR1020227043139A patent/KR20230029621A/ko unknown
- 2021-05-07 US US17/315,168 patent/US20210388054A1/en active Pending
- 2021-05-07 US US17/923,208 patent/US20230241168A1/en active Pending
- 2021-05-07 CN CN202180047833.1A patent/CN115812077A/zh active Pending
- 2021-05-07 TW TW110116616A patent/TW202208414A/zh unknown
- 2021-05-07 WO PCT/US2021/031432 patent/WO2021226553A2/en unknown
- 2021-06-11 US US17/346,095 patent/US11274140B2/en active Active
-
2022
- 2022-11-08 CL CL2022003104A patent/CL2022003104A1/es unknown
- 2022-12-07 CO CONC2022/0017780A patent/CO2022017780A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210363223A1 (en) | 2021-11-25 |
EP4146683A1 (en) | 2023-03-15 |
CO2022017780A2 (es) | 2023-03-17 |
CN117736297A (zh) | 2024-03-22 |
CN116194467A (zh) | 2023-05-30 |
WO2021226553A3 (en) | 2022-04-28 |
KR20230029621A (ko) | 2023-03-03 |
BR112022022524A2 (pt) | 2022-12-13 |
CA3178885A1 (en) | 2021-11-11 |
CA3178882A1 (en) | 2021-11-11 |
JP2023525033A (ja) | 2023-06-14 |
WO2021226551A1 (en) | 2021-11-11 |
PE20230494A1 (es) | 2023-03-23 |
JP2023525032A (ja) | 2023-06-14 |
TW202208414A (zh) | 2022-03-01 |
AU2021268033A1 (en) | 2022-12-15 |
WO2021226553A2 (en) | 2021-11-11 |
CN115812077A (zh) | 2023-03-17 |
US11274140B2 (en) | 2022-03-15 |
CN116903727A (zh) | 2023-10-20 |
EP4146684A2 (en) | 2023-03-15 |
US20210388054A1 (en) | 2021-12-16 |
CL2022003104A1 (es) | 2023-07-14 |
KR20230029622A (ko) | 2023-03-03 |
AU2021267276A1 (en) | 2022-12-15 |
MX2022013999A (es) | 2023-02-16 |
BR112022022433A2 (pt) | 2022-12-13 |
IL297980A (en) | 2023-01-01 |
IL297981A (en) | 2023-01-01 |
US20230241168A1 (en) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013998A (es) | Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas. | |
Jha et al. | Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases | |
Karanth et al. | Nature of signals that initiate the immune response during Wallerian degeneration of peripheral nerves | |
RU2013141078A (ru) | Одновалентные антигенсвязывающие белки | |
RU2012101485A (ru) | Биспецифические четырехвалентные антигенсвязывающие белки | |
Justa et al. | Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-γ responses | |
NO20054116D0 (no) | Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons | |
EA201170635A1 (ru) | Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii | |
ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
NZ594514A (en) | Interleukin-17 BINDING PROTEINS | |
TNSN08064A1 (en) | Albumin fusion proteins | |
NZ593905A (en) | Il-1 binding proteins | |
Havell et al. | Altered molecular species of human interferon produced in the presence of inhibitors of glycosylation. | |
BRPI0514395A (pt) | uso terapêutico de inibidores de rtp801 | |
EA201200515A1 (ru) | Полипептиды и их применение | |
Wang et al. | The positive effects of secreting cytokines IL-17 and IFN-γ on the early-stage differentiation and negative effects on the calcification of primary osteoblasts in vitro | |
EP4249064A3 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
BRPI0411363A (pt) | seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas | |
EP4292649A3 (en) | Fusion protein comprising nerve growth factor and preparation method and use thereof | |
Schmitz et al. | Hyaluronan oligosaccharide treatment of chondrocytes stimulates expression of both HAS-2 and MMP-3, but by different signaling pathways | |
DE60037978D1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
Mao et al. | Effect of yak milk casein hydrolysate on Th1/Th2 cytokines production by murine spleen lymphocytes in vitro | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
Saviano et al. | New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function | |
WO2010065536A3 (en) | Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases |